When the Obama administration announced its plan to test new ways of paying for prescription drugs under Medicare Part B, a slew of criticism from industry stakeholders quickly followed--though some say they see potential in the new models.
Citing a new report that found prescription drug spending reached $457 billion in 2015, the federal government announced it will test new Medicare Part B payment models to try to tackle those spiraling costs.
A new study by an advocacy group for safety-net hospitals say that participants in the 340B drug discount program spend less per patient under Medicare Part B for drugs than hospitals outside of 340B, while still caring for a population of sicker patients.
Health insurers concerned about the rising cost of prescription drugs now will have access to a new tool that lets them--and the public at large--analyze spending trends on the medicines that cost the country's largest payer the most.
After examining the expenditures on the five highest-cost Medicare Part B drugs, a report by the Government Accountability Office found that high costs were concentrated among a small number of drugs and conditions.
House Democrats say they will refuse to reduce any Medicare benefits as a way to avoid premium increases next year, according to The Hill. But while this would bode well for millions of Medicare members, it could mean a potential Democrat-Republican House grudge match.
A concerned White House and Congress are exploring strategies to mitigate the steep rise in premiums set to hit some Medicare beneficiaries next year, the New York Times reports.
A new law from the Obama administration will prohibit health insurance companies from selling Medicare supplement plans, or Medigap plans, that help consumers pay their Medicare Part B deductibles. And if an insurer breaks the law, the fine will not be cheap.
Newly released data from the Centers for Medicare & Medicaid Services show that Medicare reimbursements to doctors are far from evenly distributed, while hospital charges for top procedures and conditions have increased moderately.
Medicare spent $251 million more than it needed to on durable medical equipment infusion drugs from April 2013 to September 2014, according to a report from the Office of Inspector General--which had spelled out in a February 2013 report exactly how the Centers for Medicare & Medicaid Services could avoid overpaying for such drugs.